-
Access to HealthcareGlobal Health PartnershipsMedical InnovationsOncologySocial Commitment
-
Basel, June 16, 2022 — Many unnecessary restrictions on virtual health and care were swept away by the pandemic, and most people have embraced this new world of virtual care, according to a new report from a Broadband Commission on Sustainable Development working group. The Future of Health and Care – driving access and equity through inclusive…Global Health Partnerships
-
Basel, March 10, 2022 — Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.Global Health PartnershipsCell and Gene TherapyCancer
-
Basel, October 21, 2021 — Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding its support of the fill and finish of the Pfizer-BioNTech COVID-19 vaccine. Novartis will use its sterile manufacturing facilities at its Novartis Technical…Global Health PartnershipsDisease AwarenessAccess to Healthcare
-
Basel, June 23, 2021 — Novartis and Hewlett Packard Enterprise (HPE) today announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines.Novartis AccessGlobal Health PartnershipsFuture of HealthcareAccess to Healthcare
-
Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the…Social CommitmentGlobal Health PartnershipsFuture of HealthcareEthical Business
-
Basel, October 28, 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423. The collaboration aims to leverage Molecular Partners’…Reimagine MedicineInfectious DiseasesGlobal Health PartnershipsBiomedical Research
-
Basel, February 25, 2020 – Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world’s leading parasitic killers.Global Health PartnershipsAfricaAccess to Healthcare
-
Basel, April 2, 2020 — Novartis today announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-191-3.Social CommitmentInfectious DiseasesGlobal Health Partnerships
-
Novartis works tirelessly with third-party organizations to improve access to cancer care.
Access to HealthcareAfricaGlobal Health PartnershipsNovartis Social BusinessOncology -
In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial.
Disease EradicationGlobal Health PartnershipsMalariaNovartis Social BusinessPatient EducationTropical Diseases -
Today, many companies are trying to solve global health challenges through philanthropy. However, it has become clear that philanthropy alone is no longer enough to make a lasting impact.
Access to HealthcareFuture of HealthcareGlobal Health PartnershipsNovartis Social BusinessSustainable Development
-
Novartis works tirelessly with third-party organizations to improve access to cancer care.
-
In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial.
-
Today, many companies are trying to solve global health challenges through philanthropy. However, it has become clear that philanthropy alone is no longer enough to make a lasting impact.